Analytical Data
-
基因名
F1+2
- Application
-
别名
F1+2；Cytochrome P450 2F1
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P24903
-
表达区间
1-491aa
-
氨基酸序列
MDSISTAILLLLLALVCLLLTLSSRDKGKLPPGPRPLSILGNLLLLCSQDMLTSLTKLSKEYGSMYTVHLGPRRVVVLSGYQAVKEALVDQGEEFSGRGDYPAFFNFTKGNGIAFSSGDRWKVLRQFSIQILRNFGMGKRSIEERILEEGSFLLAELRKTEGEPFDPTFVLSRSVSNIICSVLFGSRFDYDDERLLTIIRLINDNFQIMSSPWGELYDIFPSLLDWVPGPHQRIFQNFKCLRDLIAHSVHDHQASLDPRSPRDFIQCFLTKMAEEKEDPLSHFHMDTLLMTTHNLLFGGTKTVSTTLHHAFLALMKYPKVQARVQEEIDLVVGRARLPALKDRAAMPYTDAVIHEVQRFADIIPMNLPHRVTRDTAFRGFLIPKGTDVITLLNTVHYDPSQFLTPQEFNPEHFLDANQSFKKSPAFMPFSAGRRLCLGESLARMELFLYLTAILQSFSLQPLGAPEDIDLTPLSSGLGNLPRPFQLCLRPR
-
分子量
55.5 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
F1+2 hybrid proteins are significant in the realm of molecular biology and biomedicine due to their potential applications in therapeutic development and protein engineering. These hybrid proteins typically combine functional domains from distinct proteins, thereby acquiring unique properties that can enhance their stability, specificity, or activity. Research on F1+2 restructured proteins has been driven by the need for innovative approaches to produce biopharmaceuticals with higher efficacy and reduced side effects. For instance, the fusion of antigenic epitopes from different pathogens can lead to the development of more effective vaccines. Furthermore, these proteins can be utilized in targeted drug delivery systems, where one domain can specifically bind to disease markers, while another domain carries therapeutic agents. The study of F1+2 hybrid proteins encompasses various techniques, including gene cloning, protein expression, and purification, as well as advanced structural biology methods to elucidate their mechanisms of action. Recent advancements in biotechnology and synthetic biology have expedited the design and optimization of these proteins, facilitating their application in numerous fields, such as immunology, oncology, and gene therapy. As the understanding of protein-protein interactions and folding mechanisms expands, F1+2 hybrid proteins hold great promise for yielding novel solutions to address complex diseases and enhance therapeutic strategies.
